What Arbidol Treats: Main Uses and Benefits

This medication is commonly used in the treatment and prevention of Influenza A and Influenza B, as well as general Acute Respiratory Viral Infections (ARVI). The medication is applied across domains where additional symptomatic support is needed, addressing symptom clusters that may be intense or disruptive, including fever, generalized weakness (asthenia), and muscle aches.

“The therapy is commonly used with the intent of easing the length and intensity of acute manifestations, supporting general well-being.”

Beyond active treatment, Arbidol is considered relevant for prophylaxis (prevention) and may be part of the complex treatment aimed at addressing the risks associated with secondary respiratory manifestations that can follow a primary viral illness, which is a concern for high-risk patients. It assists with maintaining functional stability during symptomatic periods.

---

Quick Fact: Support for Systemic Viral Distress The medication plays a role in managing the overall symptom load associated with acute viral infections, particularly those symptoms related to systemic imbalance and physical discomfort.

Eligibility Profile: Who Can and Cannot Use Arbidol

The official eligibility profile for Umifenovir is strictly defined by regulatory documents, distinguishing between populations permitted for use and those for whom the drug is restricted or contraindicated.

---

Contraindications and Restrictions

Absolute contraindication applies to individuals with known hypersensitivity to Umifenovir or any of its excipients. The medicine is also officially contraindicated for children under 3 years of age and during the first trimester of pregnancy. Furthermore, use is not recommended for women who are breastfeeding.

Restrictions are also applied based on comorbidities, specifically in patients with severe chronic hepatic impairment and severe chronic renal impairment, where use may be restricted or contraindicated due to the drug's metabolism and excretion route. Specific formulations may also prohibit use for patients with certain rare hereditary diseases, such as lactose intolerance.

---

Approved Populations

Umifenovir is generally indicated for use in adult patients and children 3 years of age and older, based on the established regulatory approval for specific viral indications. While older adults (over 65 years) are eligible for use, regulatory cautions may apply due to the nature of clinical data in this age group.

---

Official regulatory documents define who can and cannot use Umifenovir by establishing clear absolute contraindications based on age, hypersensitivity, and early pregnancy, while setting restricted use criteria for severe chronic organ dysfunction. These mandatory statements create the official boundaries for the legal population use of the medicine.

Interactions with other medicines and products

The official regulatory profile for Umifenovir is primarily structured around documented pharmacokinetic interaction patterns with co-administered substances.

Interaction Scope	Official Regulatory Information for Umifenovir
Medicinal Product Categories	Strong CYP3A4 inhibitors are the primary category of concern due to a recognized pharmacokinetic effect via enzyme-mediated metabolism.
Mechanistic Basis	Pharmacokinetic interaction resulting from the metabolism of Umifenovir, which is formally described as a substrate for the hepatic enzyme Cytochrome P450 3A4 (CYP3A4).
Exposure Modification	Co-administration with strong CYP3A4 inhibitors may lead to a subsequent increase in Umifenovir's systemic exposure (Area Under the Curve, AUC), as documented in regulatory-aligned studies.
Timing-based Rules	None are explicitly documented. Regulatory data confirms that food intake does not affect the bioavailability of Umifenovir, eliminating the need for dose separation from meals.
Interaction-related Restrictions	No absolute contraindications are explicitly stated in major Western regulatory labeling, which is consistent with the drug's regional licensing status.

Connection to the overall interaction profile:

The regulatory structure defines the drug’s interaction status chiefly through its CYP3A4-mediated metabolic pathway, establishing a formal risk of increased drug exposure when combined with strong inhibitors of this enzyme. The profile provides a key constraint for administration by officially stating the absence of a clinically significant drug-food interaction. This documented information restricts the type of concomitant medication based on metabolic classification.

Umifenovir acts through a concurrent dual mechanism, targeting both the viral pathogen and host immune pathways.

---

Inhibition of Viral Entry and Fusion

The primary action involves acting as a viral fusion inhibitor by directly binding to the Hemagglutinin protein on the viral surface. This molecular interaction stabilizes the protein, preventing the conformational change necessary for the virus to merge its envelope with the host cell's endosomal membrane. This action arrests the infectious cascade at the entry stage, preventing the transfer of viral genetic material to new cells.

---

Modulation of Host Innate Immunity

Umifenovir also engages a host-targeting mechanism by modulating cellular signaling, including the p38–MAPK pathway, to influence the body's non-specific defenses. This action facilitates the production of Interferons and increases the efficiency of immune cells like macrophages to perform phagocytosis. These physiological changes involve enhanced non-specific immune function and increased efficiency in the phagocytic removal of viral particles and cellular debris. The molecule exerts its function through this concurrent dual mechanism of viral propagation inhibition and host immune pathway modulation.

Official Administration Guidelines for Umifenovir (Arbidol)

The use of Umifenovir (Arbidol) is approved in specific regions, such as China and Russia, and is typically available as capsules or tablets for oral administration.

Dosing and Administration Constraints

Administration Scope	Official Guideline (Strictly Labeled)
Route of Administration	Oral (by mouth).
Timing in Relation to Meals	Must be taken on an empty stomach (before food).
Standard Treatment Frequency	Typically four times a day (q.i.d.), often specified as every six hours.

Age-Specific Dosing

The single dose amount is determined strictly by age according to official instructions:

• Children 2–7 years: 50 mg per single dose.
• Children 7–12 years: 100 mg per single dose.
• Individuals over 12 years (including adults): 200 mg per single dose.

Course Duration

For typical treatment regimens, the medication is administered at the prescribed frequency for five consecutive days. For prophylaxis (prevention) following direct contact with an infected person, the duration is commonly 10 to 14 days at a lower frequency, such as once daily.

Research Evidence / Overview of Studies for Arbidol

---

Evidence for Use in Influenza and Acute Respiratory Viral Infections (ARVI)

Clinical evaluation for the use of Umifenovir in Influenza A and B and general Acute Respiratory Viral Infections (ARVI) has primarily been conducted using short-term Randomized Controlled Trials (RCTs), where the medicine was compared against a placebo or standard supportive care. The populations studied were typically adult patients recruited in the acute phase of their illness.

The trials focused on research exploring short-term symptom changes and outcomes related to systemic or functional imbalance. Specifically, studies examined the time it took for symptoms to resolve. Some studies observed patterns where a shorter duration of heightened symptom activity was measured in the treated groups when compared to control groups. Measurements were reported within the context of short-term follow-up, corresponding to the typical course of an acute infection. The results primarily reflect studies conducted in specific regional contexts, and there is limited information for long-term outcomes.

---

Research Context for the Treatment of COVID-19

Research examined the use of Umifenovir as a component of complex treatment for COVID-19 (SARS-CoV-2 infection), involving both smaller-scale RCTs and various observational studies. Studies monitored outcomes including viral clearance and major patient outcomes such as the length of hospital stay.

The findings related to COVID-19 were mixed, indicating variability across studies. Some reports described patterns where faster viral clearance was measured in certain cohorts, while others found no difference. Findings related to major patient-important outcomes have been controversial and inconsistent. Current data are insufficient to provide definitive conclusions about the role of Umifenovir in affecting outcomes for COVID-19.

---

The Overall Evidence Landscape and Key Research Gaps

The evidence landscape is characterized by research primarily rooted in specific regions where the medicine is approved. A key research gap is the limited availability of large-scale, multi-national trials that meet the most stringent regulatory standards globally. Furthermore, controlled comparative evidence against other established antiviral treatments remains limited. The certainty of evidence for non-influenza ARVIs and COVID-19 is lower than that for Influenza, suggesting that research is ongoing and that definitive conclusions are not yet established.

Common questions about Arbidol (FAQ)

Q: Does it make you sleepy?

Official regulatory documents and product information list somnolence (sleepiness), dizziness, or drowsiness as potential undesirable effects. These effects are related to the central nervous system (CNS). Because these effects may occur, official labeling advises caution when engaging in activities such as driving or operating heavy machinery. This information summarizes the known safety profile as documented by regulatory authorities.

Q: Can children 2 years old use it?

The official product information specifies the approved age range for Arbidol. The drug is typically indicated for use in adults and adolescents aged 12 years and older, or other specific patient groups listed on the label. The official product information does not include an indication for children 2 years old. Regulatory documents establish the approved use for patients in specific age groups.

The storage and disposal of Arbidol (umifenovir) are governed by official regulatory requirements to ensure product stability and public safety.

Storage Conditions

Official labeling mandates that the product must be stored at a temperature not exceeding 25 C. The medicine must be kept protected from light and moisture and should be maintained in its original package. A critical safety requirement is that Arbidol must be kept out of the reach and sight of children at all times.

Disposal Instructions

Unused or expired Arbidol must be disposed of according to national guidelines for pharmaceutical waste. Authorities recommend utilizing an authorized drug take-back program as the preferred disposal method. If a take-back program is unavailable, the product should be mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed container, and discarded in the household trash. The empty container's personal information should be scratched out prior to disposal.